MeSHDS / README.md
Baiming123's picture
Update README.md
1162e92 verified
metadata
tags:
  - biology
size_categories:
  - 100M<n<1B

License: cc-by-nc-4.0

Description:

In this dataset, the lowest common ancestor (LCA) method was used to calculate the similarity between diseases in the MeSH (Medical Subject Headings) Tree Category C (disease) from NCBI. This dataset can be used to fine-tuning the SBERT model. The calculation process can be referred to the following article:

  @article {Chen2024.05.17.594604,
    author = {Chen, Baiming},
    title = {Refining Protein-Level MicroRNA Target Interactions in Disease from Prediction Databases Using Sentence-BERT},
    elocation-id = {2024.05.17.594604},
    year = {2024},
    doi = {10.1101/2024.05.17.594604},
    publisher = {Cold Spring Harbor Laboratory},
    abstract = {miRNAs (MicroRNAs) regulate gene expression by binding to mRNAs, inhibiting translation, or promoting mRNA degradation. miRNAs are of great importance in the development of diseases. Currently, a variety of miRNA target prediction tools are available, which analyze sequence complementarity, thermodynamic stability, and evolutionary conservation to predict miRNA-target interactions (MTIs) within the 3{\textquoteright} untranslated region (3{\textquoteright}UTR). We propose a concept for further screening sequence-based predicted MTIs by considering the disease similarity between miRNA and gene to establish a prediction database of disease-specific MTIs. We fine-tuned a Sentence-BERT model to calculate disease semantic similarity. The method achieved an F1 score of 88\% in accurately distinguishing protein-level experimentally validated MTIs and predicted MTIs. Moreover, the method exhibits exceptional generalizability across different databases. The proposed method was utilized to calculate the similarity of disease in 1,220,904 MTIs from miRTarbase, miRDB, and miRWalk, involving 6,085 genes and 1,261 pre-miRNAs. The study holds the potential to offer valuable insights into comprehending miRNA-gene regulatory networks and advancing progress in disease diagnosis, treatment, and drug development.Competing Interest StatementThe authors have declared no competing interest.},
    URL = {https://www.biorxiv.org/content/early/2024/09/18/2024.05.17.594604},
    eprint = {https://www.biorxiv.org/content/early/2024/09/18/2024.05.17.594604.full.pdf},
    journal = {bioRxiv}